Clinical trials and research studies

The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

The main objective of the study is to measure how safe and effective BT8009 (zelenectide pevedotin) is when used alone and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC).

CT-155-R-001: The purpose of this study is to investigate if digital therapeutics (a moblie software application) can help treat certain symptoms of schizophrenia. 

To evaluate the efficacy and safety of CT-155 in reducing experiential negative symptoms, compared with a Digital Control, in adult and late adolescent participants diagnosed with schizophrenia.

The purpose of this clinical trial is to assess the effectiveness of ARIKAYCE, inhaled once daily, in patient populations with mild and untreated MAC lung infection. 

Eligible patients include those who currently have a positive MAC sputum culture and have not received treatment for their infection.

TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.

PULMONARY EMBOLISM – THROMBUS REMOVAL WITH CATHETER-DIRECTED THERAPY

The study will test whether the study device, the ProVee Urethral Expander System, can be placed in your urethra safely to treat your urinary symptoms due to your enlarged prostate.

The study is designed to identify the best way to treat pulmonary embolism- with blood thinners alone or blood thinners with catheter directed therapy.

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.